EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Selective Prescribing of First‐Line SGLT2 Inhibitor and GLP ‐1 RA in Adults With Severe Mental Illness and Type 2 Diabetes

Yueh‐Yi Chiang, Chixiang Chen, Xiaojuan Li, Charmaine D. Rochester‐Eyeguokan, Wendy Camelo Castillo, Susan dosReis

Pharmacoepidemiology and Drug Safety · 2026-11 · 35 (11)

DOI: 10.1002/pds.70510 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 18.10.2026. Verfasst von Yueh‐Yi Chiang und 5 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

SGLT2 inhibitors (SGLT2i) and GLP‐1 receptor agonists (GLP‐1 RA) provide cardiovascular (CV) benefits, but their first‐line use among adults with severe mental illness (SMI) is not well characterized. We evaluated selective prescribing of SGLT2i, GLP‐1 RA, and metformin among adults with SMI and type 2 diabetes (T2D).

Methods

Using 2017–2022 Medicare claims, we identified adults with SMI and T2D who initiated first‐line SGLT2i, GLP‐1 RA, or metformin during 1/1/2018–12/31/2021. By calendar year, standardized mean differences (SMD) assessed baseline characteristic differences, and propensity score overlap coefficients (OVL) assessed group comparability between SGLT2i or GLP‐1 RA initiators and metformin initiators.

Results

We identified 1322 SGLT2i, 2306 GLP‐1 RA, and 21 144 metformin initiators. From 2018 to 2021, SGLT2i initiators shifted from younger to older than metformin initiators (SMD, −0.11 to 0.19), while differences in CVD (0.10 to 0.50) and CKD (0.18 to 0.62) increased. GLP‐1 RA initiators consistently had higher prevalence of obesity (SMD, 0.33 to 0.41) and CKD (0.42 to 0.28) than metformin initiators. Compared with metformin initiators, both SGLT2i and GLP‐1 RA initiators had lower prevalence of schizophrenia, antipsychotic use, and recent psychiatrist visits but higher prevalence of major depressive disorder; these differences generally persisted over time. OVL increased from 42.7% to 50.7% for SGLT2i and from 42.3% to 50.0% for GLP‐1 RA versus metformin.

Conclusions

First‐line SGLT2i and GLP‐1 RA prescribing among adults with SMI was selective according to cardiometabolic and mental health‐related characteristics. Future comparative studies should account for these differences and temporal prescribing changes to mitigate confounding.

Zitieren

APA

Chiang, Y., Chen, C., Li, X., Rochester‐Eyeguokan, C. D., Castillo, W. C., & dosReis, S. (2026). Selective Prescribing of First‐Line SGLT2 Inhibitor and GLP ‐1 RA in Adults With Severe Mental Illness and Type 2 Diabetes. Pharmacoepidemiology and Drug Safety, 35(11). https://doi.org/10.1002/pds.70510

Vancouver

Chiang Y, Chen C, Li X, Rochester‐Eyeguokan CD, Castillo WC, dosReis S. Selective Prescribing of First‐Line SGLT2 Inhibitor and GLP ‐1 RA in Adults With Severe Mental Illness and Type 2 Diabetes. Pharmacoepidemiology and Drug Safety. 2026;35(11). doi:10.1002/pds.70510

BibTeX
@article{Chiang2026,
  author = {Chiang, Yueh‐Yi and Chen, Chixiang and Li, Xiaojuan and Rochester‐Eyeguokan, Charmaine D. and Castillo, Wendy Camelo and dosReis, Susan},
  title = {Selective Prescribing of First‐Line SGLT2 Inhibitor and GLP ‐1 RA in Adults With Severe Mental Illness and Type 2 Diabetes},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2026},
  volume = {35},
  number = {11},
  doi = {10.1002/pds.70510}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche